115 Munson Street, Suite 101
New Haven, CT 06511
Halda Therapeutics is discovering and developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics that work by a novel hold and kill mechanism for the precision treatment of cancer. RIPTAC therapeutics are innovative heterobifunctional small molecules that hold together two proteins, a cancer-specific protein and a protein with essential function, resulting in abrogation of the essential cell function, and subsequently, cancer cell death. Halda has headquarters and labs based in New Haven, CT.